Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients

This publication has 26 references indexed in Scilit:

• Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia
  Medical Oncology, 2014
• OCT-1,ABCB1, andABCG2Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
  Chonnam Medical Journal, 2014
• The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
  Blood, 2013
• Correlation between Imatinib Trough Concentration and Efficacy in Chinese Chronic Myelocytic Leukemia Patients
  Acta Haematologica, 2012
• Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
  Clinical Cancer Research, 2009
• Molecular biology of bcr-abl1–positive chronic myeloid leukemia
  Blood, 2009
• Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
  Blood, 2007
• Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia
  Clinical Pharmacology & Therapeutics, 2007
• Chronic Myeloid Leukaemia in The 21st Century.
  2007
• Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
  Science, 2000